Melanoma is usually apparent on the skin and readily detected by trained medical providers
using a routine total body skin examination, yet this malignancy is responsible for the …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Background Stimulating an immune response against cancer with the use of vaccines remains
a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an …

Purpose In phase I/II trials, the cytotoxic T lymphocyte–associated antigen-4–blocking
monoclonal antibody tremelimumab induced durable responses in a subset of patients with …

Importance Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma
(CM) is rising despite a lack of endorsement as standard of care. Objective To develop …

PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade
and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients …

We have examined the effect of short-term and long-term growth in the absence of estrogens
on the proliferation rate and estrogen and antiestrogen responsiveness of MCF-7 human …

… Kari Kendra Kari Kendra The Ohio State University Comprehensive Cancer Center - James
Cancer Hospital and Solove Research Institute… Search for other papers by Kari Kendra in …

356154 Background: Combinations of immune checkpoint inhibitors (CPI) blocking PD-1 and
CTLA-4 or BRAF/MEK inhibitors have both shown significant antitumor efficacy and overall …

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with
continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic …